London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...

The global anti-osteoporosis therapy and fracture healing market is poised for remarkable growth, with projections indicating a rise from USD 14,051.6 million in 2023 to USD 22,427.6 million by 2033, ...

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...

ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries: London, UK Wednesday, October 9, 2024, 12:00 Hrs [IST] GSK plc announced that ...

This report highlights major developments in the health sector, including WeightWatchers offering a new obesity drug, Danco ...

Current health news highlights WeightWatchers offering a compound version of Novo Nordisk's obesity drug, Danco seeking FDA ...